Our top pick for
Allergan plc is a drug manufacturers—general business based in the US. Allergan shares (AGN) are listed on the NYSE and all prices are listed in US Dollars. Allergan employs 17,400 staff and has a trailing 12-month revenue of around USD$16.1 billion.
|52-week range||USD$158.67 - USD$202.22|
|50-day moving average||USD$188.8373|
|200-day moving average||USD$187.6554|
|Wall St. target price||USD$188.33|
|Dividend yield||USD$2.96 (1.53%)|
|Earnings per share (TTM)||USD$-25.502|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Allergan stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Allergan's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Allergan's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0492. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Allergan's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Allergan's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$7.2 billion.
The EBITDA is a measure of a Allergan's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$16.1 billion|
|Operating margin TTM||6.85%|
|Gross profit TTM||USD$13.7 billion|
|Return on assets TTM||0.74%|
|Return on equity TTM||-4.15%|
|Market capitalisation||USD$63.7 billion|
TTM: trailing 12 months
There are currently 15.0 million Allergan shares held short by investors – that's known as Allergan's "short interest". This figure is 0.1% up from 15.0 million last month.
There are a few different ways that this level of interest in shorting Allergan shares can be evaluated.
Allergan's "short interest ratio" (SIR) is the quantity of Allergan shares currently shorted divided by the average quantity of Allergan shares traded daily (recently around 4.7 million). Allergan's SIR currently stands at 3.22. In other words for every 100,000 Allergan shares traded daily on the market, roughly 3220 shares are currently held short.
However Allergan's short interest can also be evaluated against the total number of Allergan shares, or, against the total number of tradable Allergan shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Allergan's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Allergan shares in existence, roughly 50 shares are currently held short) or 0.0456% of the tradable shares (for every 100,000 tradable Allergan shares, roughly 46 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Allergan.
Find out more about how you can short Allergan stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Allergan.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 39.22
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Allergan's overall score of 39.22 (as at 03/01/2020) is pretty weak – landing it in it in the 68th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Allergan is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 5.79/100
Allergan's environmental score of 5.79 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Allergan is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 24.75/100
Allergan's social score of 24.75 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Allergan is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 16.68/100
Allergan's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Allergan is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Allergan scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Allergan hasn't always managed to keep its nose clean.
|Total ESG score||39.22|
|Total ESG percentile||67.52|
|Environmental score percentile||9|
|Social score percentile||9|
|Governance score percentile||9|
|Level of controversy||3|
We're not expecting Allergan to pay a dividend over the next 12 months.
Allergan's shares were split on a 2:1 basis on 30 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Allergan shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Allergan shares which in turn could have impacted Allergan's share price.
Over the last 12 months, Allergan's shares have ranged in value from as little as $158.67 up to $202.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Allergan's is 1.1992. This would suggest that Allergan's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.